Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Phases › Phase 2

Phase 2 (155 companies)

Companies with at least one active program at Phase 2.

Ticker Company Therapeutic areas Phase 2 programs Lead stage Mkt cap Programs
FDMT 4D Molecular Therapeutics OphthalmologyRespiratory Rare 1 Phase 3 $677M 5
ABVX Abivax Immunology 1 Phase 3 $7.50B 2
ACIU AC Immune Neurology Rare 4 Phase 3 $222M 11
ACHV Achieve Life Sciences — 1 NDA Submitted $692M 2
ACRS Aclaris Therapeutics DermatologyGI/Hepatology+1 Rare 3 Phase 2 $619M 8
ACRV Acrivon Therapeutics GI/HepatologyOncology Rare 4 Phase 2 $69.0M 9
ACTU Actuate Therapeutics Oncology 1 Phase 2 $7.9M 4
ABOS Acumen Pharmaceuticals Neurology 1 Phase 2 $16.2M 4
ADAG Adagene Oncology 3 Phase 2 $134M 10
ADCT ADC Therapeutics Oncology 3 Approved $202M 5
AGIO Agios Pharmaceuticals HematologyMetabolic Rare 1 Approved $1.76B 7
AGMB Agomab Therapeutics ImmunologyRespiratory Rare 1 Phase 2 $376M 4
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare 4 Approved $111M 10
ALLO Allogene Therapeutics ImmunologyOncology Rare 1 Phase 2 $360M 10
DRTS Alpha Tau Medical Oncology 4 Phase 2 $1.27B 6
ATHE Alterity Therapeutics Neurology Rare 1 Phase 2 $46.4M 2
ALT Altimmune GI/HepatologyMetabolic+1 2 Phase 3 $405M 3
AMLX Amylyx Pharmaceuticals MetabolicNeurology Rare 1 Phase 3 $3.79B 5
ANTX AN2 Therapeutics HematologyInfectious Disease+1 Rare 1 Phase 2 $151M 6
ANAB AnaptysBio DermatologyGI/Hepatology+2 Rare 1 Approved $1.39B 9
ANNX Annexon HematologyNeurology+2 Rare 2 Phase 3 $796M 6
APGE Apogee Therapeutics DermatologyGI/Hepatology+1 Rare 1 Phase 2 — 9
ARVN Arvinas NeurologyOncology Rare 1 Approved $420M 10
ATAI Atai Beckley Neurology 3 Phase 2 $2.73B 5
AUTL Autolus Therapeutics HematologyImmunology+3 Rare 2 Approved $341M 12
AXSM Axsome Therapeutics Neurology Rare 1 Approved $6.96B 15
BEAM Beam Therapeutics HematologyMetabolic+1 Rare 1 Phase 2 $2.73B 6
BCAX Bicara Therapeutics Oncology 1 Phase 2 $572M 4
BCYC Bicycle Therapeutics Oncology 2 Phase 2 $253M 4
BIOA BioAge Labs CardiovascularOphthalmology 2 Phase 2 $245M 2
BMEA Biomea Fusion MetabolicOncology 1 Phase 2 $41.1M 4
BDTX Black Diamond Therapeutics Oncology 2 Phase 2 $99.7M 4
CCCC C4 Therapeutics Oncology 1 Phase 2 $407M 2
CRDL Cardiol Therapeutics Cardiovascular Rare 1 Phase 3 $121M 4
RNAC Cartesian Therapeutics ImmunologyNeurology+1 Rare 1 Phase 3 $230M 4
CLDX Celldex Therapeutics DermatologyImmunology+1 1 Phase 3 $2.35B 9
CLRB Cellectar Biosciences Oncology 3 Phase 2 $11.8M 6
CRVO CervoMed Neurology Rare 3 Phase 2 $21.5M 4
CMMB Chemomab Therapeutics GI/HepatologyImmunology+1 Rare 2 Phase 2 $10.6M 4
CLNN Clene Neurology Rare 2 NDA Submitted $56.9M 5
CLYM Climb Bio HematologyImmunology+1 Rare 2 Phase 2 $604M 8
CGTX Cognition Therapeutics Neurology 2 Phase 2 $65.3M 2
CHRS Coherus Oncology Oncology 1 Approved $119M 4
CMPS COMPASS Pathways Neurology 2 NDA Submitted $1.22B 3
CMPX Compass Therapeutics Oncology 2 Phase 2 $137M 15
CGEN Compugen Oncology 1 Phase 3 $186M 7
CNTB Connect Biopharma Respiratory 4 Phase 2 $45.9M 4
CTNM Contineum Therapeutics NeurologyRespiratory Rare 3 Phase 2 $374M 4
CRVS Corvus Pharmaceuticals DermatologyOncology+1 Rare 3 Phase 3 $889M 7
COYA Coya Therapeutics Neurology Rare 1 Phase 2 $70.1M 6
CBIO Crescent Biopharma Oncology 1 Phase 2 $503M 10
CRNX Crinetics Pharmaceuticals MetabolicOncology Rare 1 Approved — 6
CUE Cue Biopharma ImmunologyOncology 1 Phase 2 $136M 6
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 1 NDA Submitted $728M 10
CYDY CytoDyn NeurologyOncology 2 Phase 2 $338M 3
DFTX Definium Therapeutics Neurology 1 Phase 3 $4.47B 4
IRON Disc Medicine GI/HepatologyHematology+2 Rare 3 Phase 3 $3.59B 9
EWTX Edgewise Therapeutics Cardiovascular 3 Phase 2 $4.93B 3
EIKN Eikon Therapeutics Oncology 2 Phase 2 $320M 13
ELDN Eledon Pharmaceuticals ImmunologyMetabolic+1 Rare 2 Phase 2 $212M 3
ELTX Elicio Therapeutics Oncology 1 Phase 2 $42.7M 6
ELOX Eloxx Pharmaceuticals DermatologyRenal Rare 1 Phase 2 $50.2M 4
ENTA Enanta Pharmaceuticals DermatologyImmunology+1 3 Approved $320M 7
ENTX Entera Bio GI/HepatologyMetabolic Rare 1 Phase 2 $547M 4
ETON Eton Pharmaceuticals GI/HepatologyInfectious Disease+3 Rare 1 Approved $1.63B 17
EVMN Evommune DermatologyImmunology+1 5 Phase 2 $241M 6
EXEL Exelixis CardiovascularOncology 3 Approved $17.0B 23
FATE Fate Therapeutics ImmunologyOncology+1 Rare 1 Phase 2 $224M 10
FBRX Forte Biosciences DermatologyGI/Hepatology 1 Phase 2 — 3
FBIO Fortress Biotech DermatologyHematology+3 Rare 1 Approved $61.7M 12
GNLX Genelux Oncology 1 Phase 3 $88.7M 3
GERN Geron Oncology 1 Approved $638M 3
GHRS GH Research NeurologyWomen's Health 3 Phase 2 $1.28B 4
GOSS Gossamer Bio Cardiovascular Rare 2 NDA Submitted — 4
HRMY Harmony Biosciences MetabolicNeurology Rare 1 Approved $1.94B 17
HROW Harrow Ophthalmology Rare 1 Approved $1.01B 15
HELP Helus Pharma Neurology 2 Phase 3 $655M 3
IMUX Immunic GI/HepatologyNeurology 1 Phase 3 $106M 4
IBRX ImmunityBio Infectious DiseaseOncology 6 Approved $9.15B 16
IMVT Immunovant ImmunologyNeurology Rare 4 Phase 3 $6.31B 5
IXHL Incannex Healthcare NeurologyRespiratory 2 Phase 2 $28.1M 2
INBX Inhibrx Biosciences Oncology 1 NDA Submitted $1.24B 6
IONS Ionis Pharmaceuticals CardiovascularHematology+5 Rare 1 Approved $6.55B 29
JBIO Jade Biosciences ImmunologyRenal Rare 1 Phase 2 $958M 4
KAPA Kairos Pharma Oncology 1 Phase 2 — 13
KZIA Kazia Therapeutics NeurologyOncology Rare 6 Phase 2 $82.0M 13
KROS Keros Therapeutics NeurologyOncology Rare 1 Phase 3 $184M 5
KPRX Kiora Pharmaceuticals Ophthalmology Rare 1 Phase 3 $6.4M 4
KYMR Kymera Therapeutics DermatologyImmunology+1 Rare 2 Phase 2 $11.2B 5
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare 2 NDA Submitted $302M 7
LBRX LB Pharmaceuticals Neurology 1 Phase 3 $1.36B 3
LCTX Lineage Cell Therapeutics MetabolicNeurology+1 Rare 1 Phase 2 $258M 12
LGVN Longeveron CardiovascularMetabolic+1 Rare 2 Phase 2 $5.8M 4
MPLT MapLight Therapeutics Neurology 3 Phase 2 $385M 6
MAZE Maze Therapeutics MetabolicRenal Rare 3 Phase 2 $1.90B 4
MDNAF Medicenna Therapeutics Oncology 1 Phase 2 $29.5M 10
MGTX MeiraGTx ImmunologyMetabolic+2 Rare 1 Phase 3 $864M 16
MLYS Mineralys Therapeutics CardiovascularRenal+1 2 NDA Submitted $1.36B 3
INKT MiNK Therapeutics ImmunologyOncology+1 Rare 3 Phase 2 $52.8M 8
MBRX Moleculin Biotech Oncology 3 Phase 2 — 8
GLUE Monte Rosa Therapeutics CardiovascularDermatology+3 Rare 2 Phase 2 $903M 7
MLTX MoonLake Immunotherapeutics DermatologyImmunology Rare 2 NDA Submitted $981M 4
NKTR Nektar Therapeutics DermatologyImmunology+2 5 Phase 3 $1.27B 11
NRSN NeuroSense Therapeutics Neurology Rare 2 Phase 2 $3.2M 3
NAMS NewAmsterdam Pharma CardiovascularMetabolic+1 1 NDA Submitted $2.27B 6
NBP NovaBridge Biosciences OncologyOphthalmology 3 Phase 2 $106M 7
NRIX Nurix Therapeutics ImmunologyNeurology+1 2 Phase 3 $1.67B 13
NVCT Nuvectis Pharma HematologyOncology+1 Rare 1 Phase 3 $719M 9
OCGN Ocugen Infectious DiseaseOphthalmology Rare 1 Phase 3 $314M 12
OCS Oculis Holding NeurologyOphthalmology Rare 1 Phase 3 $417M 5
OMER Omeros HematologyNeurology+2 Rare 1 Approved $1.22B 6
ONCY Oncolytics Biotech Oncology 2 Phase 2 $56.1M 3
IRD Opus Genetics Ophthalmology Rare 1 Approved $348M 12
ORKA Oruka Therapeutics DermatologyImmunology Rare 3 Phase 2 $6.81B 7
OVID Ovid Therapeutics Neurology Rare 1 Phase 2 $557M 4
PTN Palatin Technologies ImmunologyMetabolic+1 Rare 2 Phase 3 $11.2M 8
PALI Palisade Bio Immunology 1 Phase 2 $197M 3
PEPG PepGen Neurology Rare 1 Phase 2 $171M 1
PMVP PMV Pharmaceuticals Oncology 7 Phase 2 $67.4M 7
PCSA Processa Pharmaceuticals GI/HepatologyImmunology+2 Rare 1 Phase 2 $5.4M 7
TARA Protara Therapeutics DermatologyMetabolic+1 Rare 3 Phase 3 $142M 3
QTTB Q32 Bio Dermatology 1 Phase 2 $277M 3
QNRX Quoin Pharmaceuticals DermatologyImmunology Rare 2 Phase 2 $257M 4
RAPP Rapport Therapeutics Neurology 2 Phase 3 $1.45B 10
RXRX Recursion Pharmaceuticals Oncology 1 Phase 2 $2.19B 6
RNTX Rein Therapeutics Respiratory Rare 1 Phase 2 $53.0M 1
RLAY Relay Therapeutics DermatologyOncology Rare 1 Approved $4.11B 4
RLMD Relmada Therapeutics MetabolicNeurology+1 Rare 3 Phase 2 $416M 4
REPL Replimune Group Oncology 4 Approved $2.05B 5
RYTM Rhythm Pharmaceuticals Metabolic Rare 2 Approved $7.78B 14
RCKT Rocket Pharmaceuticals CardiovascularImmunology Rare 1 Approved $262M 4
SABS SAB Biotherapeutics Metabolic 1 Phase 2 $273M 1
SGMT Sagimet Biosciences DermatologyMetabolic 1 Phase 3 $698M 3
SLS SELLAS Life Sciences Group Oncology 1 Phase 3 $1.70B 9
SION Sionna Therapeutics Respiratory Rare 1 Phase 2 $148M 5
SYRE Spyre Therapeutics DermatologyImmunology Rare 9 Phase 2 $9.86B 10
SMMT Summit Therapeutics Oncology 2 NDA Submitted $13.1B 6
TECX Tectonic Therapeutic Cardiovascular Rare 2 Phase 2 $412M 4
TLX Telix Pharmaceuticals Oncology 3 Approved $3.27B 25
TGTX Tg Therapeutics Neurology Rare 2 Approved $9.16B 6
TLSA Tiziana Life Sciences ImmunologyNeurology Rare 4 Phase 2 $87.8M 5
TVTX Travere Therapeutics MetabolicRenal Rare 1 Approved $4.76B 7
TTRX Turn Therapeutics DermatologyInfectious Disease Rare 1 Phase 2 $282M 4
TYRA Tyra Biosciences MetabolicOncology Rare 3 Phase 2 $1.26B 5
PCVX Vaxcyte Infectious Disease 1 Phase 3 $10.1B 7
VERA Vera Therapeutics Infectious DiseaseRenal Rare 4 Approved $2.15B 6
VSTM Verastem Oncology 4 Approved $1.06B 5
VRCA Verrica Pharmaceuticals DermatologyOncology 1 Approved $54.8M 3
VKTX Viking Therapeutics MetabolicNeurology Rare 4 Phase 3 $3.42B 9
VTVT vTv Therapeutics HematologyMetabolic+1 Rare 3 Phase 3 $84.4M 9
WVE Wave Life Sciences MetabolicNeurology+1 Rare 1 Phase 2 $665M 5
XNCR Xencor ImmunologyNeurology+1 Rare 3 Approved $2.68B 28
XERS Xeris Biopharma MetabolicNeurology Rare 1 Approved $2.78B 4
ZBIO Zenas BioPharma DermatologyImmunology+2 Rare 2 NDA Submitted $1.92B 11
ZURA Zura Bio DermatologyImmunology Rare 3 Phase 2 $394M 5